Eligible subjects will have a clinical diagnosis consistent with published criteria for AD/MCI (i.e. amnestic AD or amnestic/non-amnestic mild-cognitive impairment, PCA), FTLD (i.e. bvFTD, PPA, CBD, PSP, FTD-ALS) or DLB (i.e. PD, PDD, DLB).